NCT04875585View on ClinicalTrials.gov

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

neoadjuvant therapy with Pembrolizumab/Lenvatinib

Neoadjuvant therapy for 6 weeks

PROCEDURE

Surgery

surgical resection of primary tumor and lymph-node-dissection.

DRUG

Adjuvant Treatment Phase

Adjuvant treatment with 15 cycles of Pembrolizumab

Trial Locations (1)

6020

RECRUITING

Medical University Innsbruck, Innsbruck

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical University Innsbruck

OTHER